SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : John, Mike & Tom's Wild World of Stocks -- Ignore unavailable to you. Want to Upgrade?


To: Logain Ablar who wrote (2185)2/20/2001 3:21:18 PM
From: wlheatmoon  Read Replies (1) | Respond to of 2850
 
Tim,
IMNX news today.

Immunex (IMNX: news, msgs) leapt more than 15 percent in afternoon action. The stock appears to be getting a boost from an article published in Tuesday's Wall Street Journal, which says the company is having a tough time meeting demand for its Enbrel arthritis drug treatment despite its hefty price tag. The article notes that Immunex has a waiting list of more than 1,000 to begin taking the drug, whose annual sales are already at $750 million two years after its launch.

mike